Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
BETHLEHEM, Pa., Jan. 31, 2018 -- B. Braun Medical Inc., a leader in infusion therapy and pain management, announced today that it has received U.S. Food and Drug Administration (FDA) approval for 0.9% Sodium Chloride Injection, USP in the Ecoflac™ Plus 500 mL container. Over the past few years, B. Braun worked closely with the FDA to temporarily import Ecoflac Plus under regulatory discretion from the FDA inspected sterile injectable facility in Melsungen, Germany.
The addition of Ecoflac Plus expands B. Braun’s offering of intravenous solutions and provides an additional option to administer 0.9% Sodium Chloride, which B. Braun currently offers in its EXCEL® containers, E3® containers and PAB® Partial Additive Bags.
“B. Braun is committed to helping combat the IV saline shortage in the U.S.,” said Tom Sutton, Vice President of Marketing, Medical Device and Pharmaceutical Systems at B. Braun. “This approval allows us to offer a more consistent supply of 0.9% Sodium Chloride to the market.
“We continue to work with the FDA on additional opportunities to improve market supply of IV saline,” Sutton added.
The Ecoflac Plus container is produced from a medical grade polyethylene, which is not made with natural rubber latex, Di-ethylhexyl phthalate (DEHP) or Polyvinyl Chloride (PVC). B. Braun was the first medical device manufacturer to remove harmful PVC and DEHP from many of its products. To learn more about B. Braun’s commitment to protecting people and the environment while improving patient outcomes and reducing healthcare costs visit www.bbrauncares.com.
To learn more about the Ecoflac Plus, as well as B. Braun’s full drug delivery portfolio, call 1-800-227-2862.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs.
To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Contact:
Jason Ford
B. Braun Medical Inc.
610.997.4722
[email protected]
